PCRX
Pacira BioSciences, Inc.
25.20$
+0.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 29.1% | 32.4% | 34.3% | 38.4% | 45.3% | 48.0% | 47.9% | 48.5% | 43.4% | 43.3% | 42.6% | 49.5% | |
| 6.5% | 9.7% | 11.6% | 15.0% | 16.2% | 17.8% | 17.9% | 19.5% | 11.4% | 12.5% | 11.9% | 16.5% | |
| 15.3% | 17.7% | 20.6% | 24.5% | 29.8% | 31.2% | 31.1% | 29.0% | 19.0% | 18.8% | 16.7% | 20.2% | |
| 6.3% | 6.7% | 6.4% | 6.4% | 6.6% | 7.3% | 6.6% | 7.4% | 8.9% | 9.8% | 10.4% | 10.6% | |
| 6.3% | 6.6% | 6.1% | 6.3% | 7.4% | 8.1% | 8.4% | 9.6% | 12.2% | 12.1% | 12.4% | 10.8% | |
| 10.6% | 10.4% | 10.3% | 9.9% | 0.0% | 0.0% | 1.4% | 1.3% | 1.6% | 1.6% | 1.6% | 1.6% | |
| 32.4% | 30.7% | 29.6% | 27.6% | 28.9% | 27.4% | 27.4% | 27.5% | 29.5% | 29.1% | 29.2% | 22.9% | |
| 45.8% | 44.7% | 43.7% | 46.6% | 50.7% | 49.9% | 49.7% | 50.7% | 44.0% | 45.2% | 45.9% | 46.0% | |
| 6.1% | 6.2% | 5.9% | 5.6% | 20.1% | 19.9% | 19.8% | 20.4% | 8.3% | 9.5% | 9.0% | 9.8% | |
| 1.1% | 1.1% | 1.1% | 0.6% | 13.8% | 13.6% | 13.3% | 13.8% | 0.8% | 0.8% | 0.8% | 0.8% | |
| 1.1% | 1.0% | 0.6% | 1.1% | 1.3% | 1.2% | 1.5% | 2.0% | 1.4% | 1.2% | 1.2% | 1.4% | |
| 33.6% | 32.6% | 32.3% | 35.8% | 25.4% | 24.7% | 24.0% | 24.6% | 29.0% | 29.4% | 30.4% | 29.2% | |
| 54.2% | 55.3% | 56.3% | 53.4% | 49.3% | 50.1% | 50.3% | 49.3% | 56.0% | 54.8% | 54.1% | 54.0% | |
| -8.6% | -6.8% | -6.2% | -4.8% | -14.6% | -13.3% | -12.7% | -13.4% | -15.5% | -15.8% | -16.3% | -15.4% | |
| 3.4% | 3.3% | 3.3% | 3.1% | 3.0% | 3.2% | 2.9% | 3.0% | 3.4% | 3.4% | 3.4% | 3.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.